NYSE:PHR - New York Stock Exchange, Inc. - US71944F1066 - Common Stock - Currency: USD
Phreesia (PHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stock market futures are pointing to modest gains, continuing the momentum from Tuesday’s rally. In the broader market, most megacap and growth stocks are trading marginally higher, with Nvidia and Tesla leading gains. Investor attention is focused on Nvidia’s upcoming earnings report, scheduled for release after the market closes today, while investors also await the minutes from the Federal Reserve’s latest policy meeting, which may provide further insights into the central bank’s stance on in
The headline numbers for Phreesia (PHR) give insight into how the company performed in the quarter ended April 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Phreesia (PHR) delivered earnings and revenue surprises of 46.15% and 1.09%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
Beyond analysts' top -and-bottom-line estimates for Phreesia (PHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended April 2025.
Privia Health (PRVA) delivered earnings and revenue surprises of -50% and 5.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: PRVA
TruBridge (TBRG) delivered earnings and revenue surprises of -2.70% and 1.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: TBRG
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Phreesia (NYSE:PHR) and its peers.
Healthcare technology company Phreesia (NYSE:PHR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 15.4% year on year to $109.7 million. The company expects the full year’s revenue to be around $477 million, close to analysts’ estimates. Its GAAP loss of $0.11 per share was 35% above analysts’ consensus estimates.
Healthcare technology company Phreesia (NYSE:PHR) will be reporting results tomorrow after the bell. Here’s what to look for.